A
Ahmed Sawas
Researcher at Columbia University Medical Center
Publications - 78
Citations - 1349
Ahmed Sawas is an academic researcher from Columbia University Medical Center. The author has contributed to research in topics: Brentuximab vedotin & Population. The author has an hindex of 14, co-authored 69 publications receiving 955 citations. Previous affiliations of Ahmed Sawas include New York University & Columbia University.
Papers
More filters
Journal ArticleDOI
Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma.
Ann S. LaCasce,R. Gregory Bociek,Ahmed Sawas,Paolo Caimi,Edward Agura,Jeffrey Matous,Stephen M. Ansell,Howland E. Crosswell,Miguel Islas-Ohlmayer,Caroline Behler,Eric C. Cheung,Andres Forero-Torres,Julie M. Vose,Owen A. O'Connor,Neil C Josephson,Yinghui Wang,Ranjana H. Advani +16 more
TL;DR: BV plus bendamustine as first salvage therapy in relapsed/refractory HL is highly active with a manageable toxicity profile and a protocol amendment requiring premedication reduced IRR severity.
Journal ArticleDOI
A phase 1 study of romidepsin and pralatrexate reveals marked activity in relapsed and refractory T-cell lymphoma
Jennifer E Amengual,Renee Lichtenstein,Jennifer K. Lue,Ahmed Sawas,Changchun Deng,Emily Lichtenstein,Karen Khan,Laine Atkins,Aishling M. Rada,Hye A. Kim,Codruta Chiuzan,Matko Kalac,Enrica Marchi,Lorenzo Falchi,Mark A. Francescone,Lawrence B. Schwartz,Serge Cremers,Owen A. O'Connor +17 more
TL;DR: The phase 1 study of pralatrexate plus romidepsin resulted in a high response rate in patients with previously treated PTCL, and a phase 2 study in P TCL will determine the efficacy of the combination.
Journal ArticleDOI
Oral 5-azacytidine and romidepsin exhibit marked activity in patients with PTCL: a multicenter phase 1 study.
Owen A. O'Connor,Lorenzo Falchi,Jennifer K. Lue,Enrica Marchi,Cristina Kinahan,Ahmed Sawas,Changchun Deng,Francesca Montanari,Jennifer E Amengual,Hye A. Kim,Aishling M. Rada,Karen Khan,Alice T. Jacob,Michelle Malanga,Mark M. Francescone,Renu Nandakumar,Craig R. Soderquist,David C. Park,Govind Bhagat,Bin Cheng,Alberto Risueño,Daniel Menezes,Andrei R. Shustov,Lubomir Sokol,Luigi Scotto +24 more
TL;DR: The combination of oral 5-azacytidine and romidepsin was substantially more active in patients with PTCL than non-T-cell lymphoma and found an association between response and level of demethylation or tumor mutational profile.
Journal ArticleDOI
A neglected gland: a review of Cowper's gland.
TL;DR: This review provides a comprehensive report on the development, function and various lesions associated with Cowper's gland.
Journal ArticleDOI
Phase I Study of the CD47 Blocker TTI-621 in Patients with Relapsed or Refractory Hematologic Malignancies.
Stephen M. Ansell,Michael B. Maris,Alexander M. Lesokhin,Robert W. Chen,Ian W. Flinn,Ahmed Sawas,Mark D. Minden,Diego Villa,Mary Elizabeth Percival,Mary Elizabeth Percival,Anjali S. Advani,James M. Foran,Steven M. Horwitz,Matthew Mei,Jasmine Zain,Kerry J. Savage,Christiane Querfeld,Oleg E. Akilov,Lisa Johnson,Tina Catalano,Penka S. Petrova,Robert A. Uger,Eric L. Sievers,Anca Milea,Kathleen Roberge,Yaping Shou,Owen A. O'Connor +26 more
TL;DR: In this paper, TTI-621 (SIRPα-IgG1 Fc) is a checkpoint inhibitor that activates antitumor activity by blocking the CD47 "don9t eat me" signal.